Asthma, BronchialAIR POWERNCT06422078
A Non-interventional, Prospective Study With Benralizumab
An observational study of Asthma, Bronchial, run by AstraZeneca at 41 sites in Germany.
Trial summary
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in a real-life setting in Germany. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Asthma, Bronchial
- How many people
- 300 participants
- Where
- 41 sitesGermany
- Study dates
- 25 Jul 2024to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will consist of adult patients, who were diagnosed with severe eosinophilic asthma treated by pulmonary specialists, for whom the indication to start benralizumab therapy was received independently of study participation.
Who may be able to join
- Male or female patients aged 18 years or older
- Confirmed diagnosis of severe eosinophilic asthma (defined according to the European Respiratory Society and American Thoracic Society and local German guidelines) treated with high-dose inhaled corticosteroids (ICS) plus long-acting beta agonists (LABA)
- Prescribed treatment with benralizumab according to label and local market reimbursement criteria
- Benralizumab treatment was not part of the study decision and treatment decision was met prior and independently of the study
- Patients must be able and willing to read and comprehend written instructions
- After full explanation, patients must have signed an informed consent form (ICF) indicating that they understand the purpose of, and the procedures required for the study and are willing to participate in the study
- Patients must be willing to report asthma patient-reported outcomes (PROs) every 4 weeks and medication intake weekly
Who cannot join
- Patients who participate in an observational trial that might, in the investigators' opinion, influence the assessment for current study; or participated in a randomized clinical trial in the last 3 months
- History of anaphylaxis to any biologic therapy
- Prior treatment with any asthma biologic therapy within the last 3 months
- Concurrent asthma biologic therapy
- Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent was obtained that had not been treated with, or had failed to respond to standard of care (SOC) therapy
- Any other pulmonary disease than asthma that, in the investigator's point of view, would have an impact on the interpretation of results
Show all 12Show fewer
- An acute or chronic condition that, in the investigator's point of view, would limit the patient's ability to complete questionnaires or participate in this study or impact the interpretations of results
- Current or history of malignancy within 5 years before the enrolment date with the following exceptions:
- In-situ carcinoma of the cervix where curative therapy has been completed and patients are in remission for at least 12 months prior to enrolment date
- Basal cell or superficial squamous skin cancer
- Pregnancy or lactation period (status to be proactively asked by the investigator)
- Any condition, that, in the opinion of the investigator, could jeopardize the safety of the patient
Trial locations and contacts
41 sites in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
41 sites in 1 country
Germany41 sites, 40 recruiting
- Recruiting
Research Site
Ahrensburg
- Recruiting
Research Site
Ansbach
- Recruiting
Research Site
Aschaffenburg
- Recruiting
Research Site
Auerbach
- Recruiting
Research Site
Augsburg
- Recruiting
Research Site
Bad Homburg
- Recruiting
Research Site
Berlin
- Recruiting
Research Site
Cottbus
- Recruiting
Research Site
Darmstadt
- Recruiting
Research Site
Dresden
- Recruiting
Research Site
Düsseldorf
- Recruiting
Research Site
Ehringshausen
- Recruiting
Research Site
Erkelenz
- Recruiting
Research Site
Essen
- Recruiting
Research Site
Flensburg
- Recruiting
Research Site
Frankfurt am Main
- Recruiting
Research Site
Garmisch-Partenkirchen
- Recruiting
Research Site
Halle
- Recruiting
Research Site
Hamburg
- Recruiting
Research Site
Hanover
- Withdrawn
Research Site
Heidelberg
- Recruiting
Research Site
Heidelberg
- Recruiting
Research Site
Hohenstein-Ernsttahl
- Recruiting
Research Site
Itzehoe
- Recruiting
Research Site
Jena
- Recruiting
Research Site
Leipzig
- Recruiting
Research Site
Loerrach
- Recruiting
Research Site
Lübeck
- Recruiting
Research Site
Lüneburg
- Recruiting
Research Site
Markkleeberg
- Recruiting
Research Site
Mönchengladbach
- Recruiting
Research Site
Neuruppin
- Recruiting
Research Site
Nuremberg
- Recruiting
Research Site
Papenburg
- Recruiting
Research Site
Rostock
- Recruiting
Research Site
Saalfeld
- Recruiting
Research Site
Spardorf
- Recruiting
Research Site
Weißenburg
- Recruiting
Research Site
Wilhelmshaven
- Recruiting
Research Site
Würzburg
- Recruiting
Research Site
Zossen
About this study
Official title: A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in a real-life setting in Germany.
Read the detailed description
This is a prospective observational study to investigate the asthma control and health realted quality of life (HRQL) of benralizumab treated patients in routine clinical practice, their asthma medication intake, and their changes in asthma medication during the study, up to 52 weeks.
The asthma control will be analyzed by using the Asthma Control Test (ACT) and the Asthma Impairment and Risk Questionnaire (AIRQ®) at different timepoints during the study period either collected by the investigator or self-reported by the patient. In addition, health realted quality of life will be assessed at baseline and routine follow-up visits using the mini Asthma Quality of Life Questionnaire (miniAQLQ) which is collected by the investigator. To investigate the medication intake and assess the changes in asthma medication, the patients will record their weekly medication intake in a paper-based or an electronic medication diary throughout the study.
- Conditions
- Asthma, Bronchial
- Keywords
- benralizumab, severe eosinophilic asthma, quality of life, asthma control
- Medical subject headings
- Asthma, Pulmonary Eosinophilia
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose
To assess asthma control in patients initiating treatment with benralizumab over time.
The ACT includes 5 questions. The score can range from 5 (worst control) to 25 (best control). Scores between 20 and 25 indicate well-controlled asthma, and scores lower than 20 indicate patients with not-well controlled asthma.
Measured: From baseline to week 12, 24 and 52
Proportion of responders at baseline, week 12, 24 and 52 after first benralizumab dose, using ACT
To assess asthma control in patients initiating treatment with benralizumab. Responders are defined as patients with well-controlled asthma (ACT score ≥20).
Measured: At baseline, week 12, 24 and 52
Change in daily doses of prescribed inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose
To assess prescribed daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.
Measured: From baseline to week 12, 24 and 52
Change in daily doses of patient-reported inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose
To assess patient-reported daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.
Measured: From baseline to week 12, 24 and 52
Reduction (in percentage) in prescribed daily ICS dose intake from baseline to week 52 after first benralizumab dose
To assess prescribed daily ICS dose of benralizumab treated patients with ICS dose reduction.
Measured: From baseline to week 52
Reduction (in percentage) in patient-reported daily ICS dose intake from baseline to week 52 after first benralizumab dose
To assess patient-reported daily ICS dose of benralizumab treated patients with ICS dose reduction.
Measured: From baseline to week 52
Secondary outcomes (19)
Proportion of patients meeting any individual criteria for remission at baseline, week 24 and 52 after first benralizumab dose
To describe the proportion of patients who meet any individual criteria for remission.
Criteria for remission are defined as no exacerbation, no prescribed use of oral corticosteroids (OCS) for asthma, ACT score ≥20, and stable lung function).
Measured: At baseline, week 24 and 52
Proportion of patients fulfilling all the criteria for remission at baseline, week 24 and 52 after first benralizumab dose
To describe the proportion of patients who meet all criteria for remission after initiation of benralizumab treatment.
Measured: At baseline, week 24 and 52
Total Asthma Impairment and Risk Questionnaire® (AIRQ®) score reduction from baseline to every 4 weeks after first benralizumab dose
To assess diaries reported asthma control in patients initiating treatment with benralizumab using the AIRQ® score.
The AIRQ® includes 10 questions (7 assessing symptom impairment and 3 assessing risk) concerning patient medication use, asthma symptoms, medical visits, and tests. The AIRQ® can predict the risk for exacerbations and assess the quality of life of asthma patients.
AIRQ® score: well-controlled (0-1 points), not well-controlled (2-4 points) and very poorly controlled (≥5 points) asthma
Measured: From baseline to week 52
Total ACT score reduction from baseline to every 4 weeks after first benralizumab dose
To assess diaries reported asthma control in patients initiating treatment with benralizumab using the ACT score.
Measured: From baseline to week 52
Change in total Mini Asthma Quality of Life Questionnaire (miniAQLQ) score from baseline to week 12, 24, and 52 after first benralizumab dose
To describe patient-reported health-related quality of life (HRQL) in patients initiating treatment with benralizumab using the miniAQLQ.
The miniAQLQ is composed of 15 questions covering 4 different domains, namely symptoms, activities, emotions, and environment experienced during the previous 2 weeks. The score in each item can vary from 1 to 7, with a higher score indicating better quality of life (QoL). The mean score is calculated as the total score divided by the number of items, and the domain scores are calculated as the total score divided by the number of items for respective domain. A change in score of ≥0.5 can be considered clinically important
Measured: From baseline to week 12, 24 and 52
Change in daily doses of prescribed relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
To describe the proportion of patients regarding prescribed standard-of-care (SOC) asthma medication dose change in patients initiating treatment with benralizumab.
Measured: From baseline to week 12, 24 and 52
Proportion of patients with increased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
To describe the proportion of patients regarding prescribed increased SOC asthma medication dose in patients initiating treatment with benralizumab.
Measured: From baseline to week 12, 24 and 52
Proportion of patients with decreased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
To describe the proportion of patients regarding prescribed decreased SOC asthma medication dose in patients initiating treatment with benralizumab.
Measured: From baseline to week 12, 24 and 52
Proportion of patients with equal daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
To describe the proportion of patients regarding prescribed equal SOC asthma medication dose in patients initiating treatment with benralizumab.
Measured: From baseline to week 12, 24 and 52
Annualized exacerbation rate assessed at baseline, week 12, 24 and 52 after first benralizumab dose
To assess the annualized asthma exacerbation rate in patients initiating treatment with benralizumab.
Measured: From baseline to week 12, 24 and 52
Proportion of patients without exacerbations at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the proportion of patients without asthma exacerbations in patients initiating treatment with benralizumab.
Measured: From baseline to week 12, 24 and 52
Level of lung function parameters - forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the FEV1 and FVC levels in patients initiating treatment with benralizumab.
From FEV1 and FVC the Tiffenau-Index will be calculated as follows: FEV1/FVC
Measured: At baseline, week 12, 24 and 52
Level of lung function parameters - residual volume (RV) at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the level of RV in patients initiating treatment with benralizumab.
Measured: At baseline, week 12, 24 and 52
Level of lung function parameters - total lung capacity (TLC) at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the level of TLC in patients initiating treatment with benralizumab.
Measured: At baseline, week 12, 24 and 52
Level of lung function parameters - total specific airway resistance (sRtot) at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the level of sRtot in patients initiating treatment with benralizumab.
Measured: At baseline, week 12, 24 and 52
Level of diffusing capacity of the lungs for carbon monoxide (DLCO) at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the level of DLCO in patients initiating treatment with benralizumab.
Measured: At baseline, week 12, 24 and 52
Level of biomarkers - eosinophils at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the level of eosinophils in patients initiating treatment with benralizumab.
Measured in cells per microliter.
Measured: At baseline, week 12, 24 and 52
Level of biomarkers - total immunglobulin E (IgE) at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the level of total IgE in patients initiating treatment with benralizumab.
Total IgE, measured in international units per milliliter (IU/ml).
Measured: At baseline, week 12, 24 and 52
Level of biomarkers - fractional exhaled nitric oxide (FeNO) at baseline, week 12, 24 and 52 after first benralizumab dose
To describe the level of FeNO in patients initiating treatment with benralizumab.
Measured in parts per billion (ppb).
Measured: At baseline, week 12, 24 and 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2024
- Study start25 Jul 2024
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asthma, BronchialStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06422078
- Sponsor's protocol ID
- D3250R00124
- Acronym
- AIR POWER
- Status last verified
- Aug 2026
- First submitted
- 15 May 2024
- Last updated
- 28 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life
- ClinicalTrials.gov ID
- NCT06422078
- Acronym / sponsor ID
- AIR POWER / D3250R00124
- Conditions
- Asthma, Bronchial
- Keywords
- benralizumab, severe eosinophilic asthma, quality of life, asthma control
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 25 Jul 2024 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 20 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in a real-life setting in Germany.
Detailed description
This is a prospective observational study to investigate the asthma control and health realted quality of life (HRQL) of benralizumab treated patients in routine clinical practice, their asthma medication intake, and their changes in asthma medication during the study, up to 52 weeks.
The asthma control will be analyzed by using the Asthma Control Test (ACT) and the Asthma Impairment and Risk Questionnaire (AIRQ®) at different timepoints during the study period either collected by the investigator or self-reported by the patient. In addition, health realted quality of life will be assessed at baseline and routine follow-up visits using the mini Asthma Quality of Life Questionnaire (miniAQLQ) which is collected by the investigator. To investigate the medication intake and assess the changes in asthma medication, the patients will record their weekly medication intake in a paper-based or an electronic medication diary throughout the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of adult patients, who were diagnosed with severe eosinophilic asthma treated by pulmonary specialists, for whom the indication to start benralizumab therapy was received independently of study participation.
Key inclusion criteria (7 listed)
- Male or female patients aged 18 years or older
- Confirmed diagnosis of severe eosinophilic asthma (defined according to the European Respiratory Society and American Thoracic Society and local German guidelines) treated with high-dose inhaled corticosteroids (ICS) plus long-acting beta agonists (LABA)
- Prescribed treatment with benralizumab according to label and local market reimbursement criteria
- Benralizumab treatment was not part of the study decision and treatment decision was met prior and independently of the study
- Patients must be able and willing to read and comprehend written instructions
Key exclusion criteria (12 listed)
- Patients who participate in an observational trial that might, in the investigators' opinion, influence the assessment for current study; or participated in a randomized clinical trial in the last 3 months
- History of anaphylaxis to any biologic therapy
- Prior treatment with any asthma biologic therapy within the last 3 months
- Concurrent asthma biologic therapy
- Helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent was obtained that had not been treated with, or had failed to respond to standard of care (SOC) therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
To assess asthma control in patients initiating treatment with benralizumab over time. The ACT includes 5 questions. The score can range from 5 (worst control) to 25 (best control). Scores between 20 and 25 indicate well-controlled asthma, and scores lower than 20 indicate patients with not-well controlled asthma.
Proportion of responders at baseline, week 12, 24 and 52 after first benralizumab dose, using ACT
Time frame: At baseline, week 12, 24 and 52
To assess asthma control in patients initiating treatment with benralizumab. Responders are defined as patients with well-controlled asthma (ACT score ≥20).
Change in daily doses of prescribed inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
To assess prescribed daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.
Change in daily doses of patient-reported inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
To assess patient-reported daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.
Reduction (in percentage) in prescribed daily ICS dose intake from baseline to week 52 after first benralizumab dose
Time frame: From baseline to week 52
To assess prescribed daily ICS dose of benralizumab treated patients with ICS dose reduction.
Reduction (in percentage) in patient-reported daily ICS dose intake from baseline to week 52 after first benralizumab dose
Time frame: From baseline to week 52
To assess patient-reported daily ICS dose of benralizumab treated patients with ICS dose reduction.
19 secondary outcomes
Proportion of patients meeting any individual criteria for remission at baseline, week 24 and 52 after first benralizumab dose
Time frame: At baseline, week 24 and 52
Proportion of patients fulfilling all the criteria for remission at baseline, week 24 and 52 after first benralizumab dose
Time frame: At baseline, week 24 and 52
Total Asthma Impairment and Risk Questionnaire® (AIRQ®) score reduction from baseline to every 4 weeks after first benralizumab dose
Time frame: From baseline to week 52
Total ACT score reduction from baseline to every 4 weeks after first benralizumab dose
Time frame: From baseline to week 52
Change in total Mini Asthma Quality of Life Questionnaire (miniAQLQ) score from baseline to week 12, 24, and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
Change in daily doses of prescribed relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
Proportion of patients with increased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
Proportion of patients with decreased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
Proportion of patients with equal daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
Annualized exacerbation rate assessed at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
Proportion of patients without exacerbations at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: From baseline to week 12, 24 and 52
Level of lung function parameters - forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Level of lung function parameters - residual volume (RV) at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Level of lung function parameters - total lung capacity (TLC) at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Level of lung function parameters - total specific airway resistance (sRtot) at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Level of diffusing capacity of the lungs for carbon monoxide (DLCO) at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Level of biomarkers - eosinophils at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Level of biomarkers - total immunglobulin E (IgE) at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Level of biomarkers - fractional exhaled nitric oxide (FeNO) at baseline, week 12, 24 and 52 after first benralizumab dose
Time frame: At baseline, week 12, 24 and 52
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Related trials for Asthma, Bronchial
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Active, not recruiting
Community Health Equity Accelerator (CHEA) Pediatric Asthma Intervention
Asthma in Children
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
RecruitingObservational study
NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
41 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma, Bronchial, run by AstraZeneca at 41 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 41 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose (time frame: From baseline to week 12, 24 and 52). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.